Arzu Yaren

Pamukkale University — Turkey

Medicine · Health Sciences

18h-index874citations116works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(10), Inflammatory Biomarkers in Disease Prognosis(10), Advanced Breast Cancer Therapies(10), Breast Cancer Treatment Studies(9), Cancer Diagnosis and Treatment(9)

Publications116 total

Early On-Treatment Nutritional Change and Baseline Inflammation Stratify Outcomes in Patients Receiving Immune Checkpoint Inhibitors
The European Research Journal·2026Open Access
Role of Prognostic Nutritional Index and C-Reactive Protein/Albumin Ratio in Prognosis of Locally Advanced Nasopharyngeal Carcinoma
Medicina·2026Open Access
Differential Metastatic Patterns and Prognostic Value of Systemic Inflammation Scores in Anaplastic Lymphoma Kinase Rearranged Versus Anaplastic Lymphoma Kinase Negative Non-Small Cell Lung Cancer
Cancers·2026Open Access
Prognostic Value of Systemic Inflammatory Markers in Locally Advanced or Metastatic Melanoma: A Real-World Analysis
Cancers·2026Open Access
Real-World Outcomes of Treatment Approaches and the Impact of Systemic Inflammation Markers on Survival in Patients with Locally Advanced and Metastatic Laryngeal Cancer
Journal of Clinical Medicine·2025Open Access
Lymphocyte-Associated Inflammation Markers Predict Bleomycin-Induced Pulmonary Toxicity in Testicular Cancer
Journal of Clinical Medicine·2025Open Access
Sarcopenic Obesity and Sarcopenic Visceral Obesity, Calculated Using the Skeletal Muscle İndex and Visceral Fat İndex at the L3 Vertebra Level, Do Not Predict Survival Rates in Endometrial Cancer Patients
Journal of Clinical Medicine·2025Open Access
Lymphocyte-Associated Inflammation Markers Predict Bleomycin-Induced Pulmonary Toxicity in Testicular Cancer
Preprints.org·2025Open Access
Prognostic Value of a New Marker, IBI Score and NLR Change in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors (Prognostic value of IBI score and NLR change in NSCLC)
Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi·2025Open Access
HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy
Turkish Journal of Clinics and Laboratory·2025· 1 citedOpen Access
The impact of SARS-CoV-2 infection on the survival in NSCLC patients undergoing immunotherapy
Pamukkale Medical Journal·2025Open Access
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
Clinical Breast Cancer·2025· 2 cited
Characterization of lncRNAs contributing to drug resistance in epithelial ovarian cancer
Medical Oncology·2025· 2 citedOpen Access
Hormon reseptörü pozitif, HER2 negatif metastatik meme kanseri tanısıyla ribosiklib veya palbosiklib ile letrozol kombinasyon tedavisi verilen hastalarda HER2-düşük ekspresyonunun önemi
DergiPark (Istanbul University)·2025Open Access
Deeply Saddening Life Events Play a Carcinogenic Role by Inducing Mutations in ALOX12 and FKBP5 Genes
Genes·2024Open Access
Use of albumin and CRP related immuno-nutritional markers for prediction of locoregional response to treatment in unresectable hepatocellular carcinoma
Pamukkale Medical Journal·2024Open Access
Prognostic Value of ALBI Score and Lymphocyte-Associated Inflammation Markers in Advanced Hepatocellular Carcinoma: A Single Centre Retrospective Cross-Sectional Study
Namık Kemal Tıp Dergisi·2024Open Access
The effect of genetic alterations detected by the circulating tumor DNA-based next-generation sequencing technique on prognosis and survival in metastatic colorectal cancer
Pamukkale Medical Journal·2024Open Access
Categorized Serum miRNAs as Potential Biomarkers for Predicting the Progression and Prognosis of Colorectal Cancer
Iranian Journal of Blood and Cancer·2024· 1 citedOpen Access
223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study
ESMO Open·2024· 2 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Serkan Değirmencioğlu(13), Gamze Gököz Doğu(12), İlhan Öztop(10), Atike Gökçen Demiray(8), Tuğba Yavuzşen(8), Burçin Çakan Demirel(8), Semra Paydaş(8), Özgür Tanrıverdi(7), Burcu Yapar Taşköylü(7), Sebahat Turgut(6), Aydın Demiray(6), Ergün Erdem(6), Seda Kahraman(6), Nuri Karadurmuş(6), Mehmet Alı Nahıt Şendur(6), Ferda Bir(5), İbrahim Vedat Bayoğlu(5), Esin Oktay(5), Serkan Menekşe(5), Canan Kelten(5)